Publication:
Twice daily deferasirox significantly improves clinical efficacy in transfusion dependent thalassaemias who were inadequate responders to standard once daily dose

Simple item page
dc.contributor.authorBunchoo Pongtanakulen_US
dc.contributor.authorVip Viprakasiten_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-10-19T04:37:27Z
dc.date.available2018-10-19T04:37:27Z
dc.date.issued2013-08-01en_US
dc.identifier.citationBlood Cells, Molecules, and Diseases. Vol.51, No.2 (2013), 96-97en_US
dc.identifier.doi10.1016/j.bcmd.2013.03.004en_US
dc.identifier.issn10960961en_US
dc.identifier.issn10799796en_US
dc.identifier.other2-s2.0-84878403678en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/31256
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84878403678&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectMedicineen_US
dc.titleTwice daily deferasirox significantly improves clinical efficacy in transfusion dependent thalassaemias who were inadequate responders to standard once daily doseen_US
dc.typeLetteren_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84878403678&origin=inwarden_US

Files

Collections

Scopus 2011-2015